Do analysts rate PLRZ or PLYX?

Polaryx Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 295.26%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Polaryx Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, PLRZ or PLYX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Polaryx Therapeutics N/A N/A N/A N/A N/A

Is PLRZ or PLYX more profitable?

Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A Polaryx Therapeutics N/A N/A N/A

Do analysts recommend FTLF or PLRZ?

FitLife Brands presently has a consensus target price of $21.50, indicating a potential upside of 94.39%. Given FitLife Brands' stronger consensus rating and higher possible upside, research analysts clearly believe FitLife Brands is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FitLife Brands 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, FTLF or PLRZ?

FitLife Brands has higher revenue and earnings than Polyrizon. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FitLife Brands $81.46M 1.27 $6.33M $0.60 18.43 Polyrizon N/A N/A -$3.34M N/A N/A

Does the media favor FTLF or PLRZ?

In the previous week, FitLife Brands had 1 more articles in the media than Polyrizon. MarketBeat recorded 5 mentions for FitLife Brands and 4 mentions for Polyrizon. Polyrizon's average media sentiment score of 1.87 beat FitLife Brands' score of 1.01 indicating that Polyrizon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FitLife Brands 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Polyrizon 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer AADI or PLRZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, AADI or PLRZ?

Polyrizon has lower revenue, but higher earnings than Aadi Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aadi Bioscience $25.07M 4.10 -$65.76M -$2.35 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Do analysts prefer ANIX or PLRZ?

Anixa Biosciences presently has a consensus price target of $8.50, suggesting a potential upside of 198.25%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Anixa Biosciences is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anixa Biosciences 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, ANIX or PLRZ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anixa Biosciences N/A N/A -$10.93M -$0.31 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is ANIX or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -71.12% -62.88% Polyrizon N/A N/A N/A

Does the media refer more to ANIX or PLRZ?

In the previous week, Anixa Biosciences had 1 more articles in the media than Polyrizon. MarketBeat recorded 5 mentions for Anixa Biosciences and 4 mentions for Polyrizon. Polyrizon's average media sentiment score of 1.87 beat Anixa Biosciences' score of 0.91 indicating that Polyrizon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Polyrizon 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate TELO or PLRZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, TELO or PLRZ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is TELO or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -201.23% -172.71% Polyrizon N/A N/A N/A

Does the media refer more to TELO or PLRZ?

In the previous week, Polyrizon had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 4 mentions for Polyrizon and 2 mentions for Telomir Pharmaceuticals. Polyrizon's average media sentiment score of 1.87 beat Telomir Pharmaceuticals' score of 1.31 indicating that Polyrizon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telomir Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Polyrizon 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Polyrizon (PLRZ) Competitors

$12.75 +1.27 (+11.06%)

Closing price 04:00 PM Eastern

Extended Trading

$12.13 -0.62 (-4.89%)

As of 07:40 PM Eastern

Compare

PLRZ vs. PLYX, FTLF, AADI, ANIX, and TELO

Should you buy Polyrizon stock or one of its competitors? MarketBeat compares Polyrizon with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Polyrizon include Polaryx Therapeutics (PLYX), FitLife Brands (FTLF), Aadi Bioscience (AADI), Anixa Biosciences (ANIX), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry.

How does Polyrizon compare to Polaryx Therapeutics?

Polyrizon (NASDAQ:PLRZ) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

In the previous week, Polyrizon had 3 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 4 mentions for Polyrizon and 1 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 1.89 beat Polyrizon's score of 1.87 indicating that Polaryx Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Polyrizon	Very Positive
Polaryx Therapeutics	Very Positive

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Polaryx Therapeutics	N/A	N/A	N/A

Polaryx Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 295.26%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A

Summary

Polaryx Therapeutics beats Polyrizon on 4 of the 5 factors compared between the two stocks.

How does Polyrizon compare to FitLife Brands?

FitLife Brands (NASDAQ:FTLF) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

FitLife Brands has a beta of 0.02, suggesting that its stock price is 98% less volatile than the broader market. Comparatively, Polyrizon has a beta of -1.91, suggesting that its stock price is 291% less volatile than the broader market.

2.3% of FitLife Brands shares are held by institutional investors. 61.4% of FitLife Brands shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, FitLife Brands had 1 more articles in the media than Polyrizon. MarketBeat recorded 5 mentions for FitLife Brands and 4 mentions for Polyrizon. Polyrizon's average media sentiment score of 1.87 beat FitLife Brands' score of 1.01 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FitLife Brands	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Polyrizon	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

FitLife Brands has a net margin of 6.64% compared to Polyrizon's net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Polyrizon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
Polyrizon	N/A	N/A	N/A

FitLife Brands has higher revenue and earnings than Polyrizon.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$81.46M	1.27	$6.33M	$0.60	18.43
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

FitLife Brands presently has a consensus target price of $21.50, indicating a potential upside of 94.39%. Given FitLife Brands' stronger consensus rating and higher possible upside, research analysts clearly believe FitLife Brands is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

FitLife Brands beats Polyrizon on 12 of the 13 factors compared between the two stocks.

How does Polyrizon compare to Aadi Bioscience?

Aadi Bioscience (NASDAQ:AADI) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

In the previous week, Polyrizon had 4 more articles in the media than Aadi Bioscience. MarketBeat recorded 4 mentions for Polyrizon and 0 mentions for Aadi Bioscience. Polyrizon's average media sentiment score of 1.87 beat Aadi Bioscience's score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Polyrizon	Very Positive

52.1% of Aadi Bioscience shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aadi Bioscience has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Polyrizon has a beta of -1.91, suggesting that its share price is 291% less volatile than the broader market.

Polyrizon has lower revenue, but higher earnings than Aadi Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.10	-$65.76M	-$2.35	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Polyrizon has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Polyrizon's return on equity of 0.00% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Polyrizon	N/A	N/A	N/A

Summary

Polyrizon beats Aadi Bioscience on 7 of the 11 factors compared between the two stocks.

How does Polyrizon compare to Anixa Biosciences?

Anixa Biosciences (NASDAQ:ANIX) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

In the previous week, Anixa Biosciences had 1 more articles in the media than Polyrizon. MarketBeat recorded 5 mentions for Anixa Biosciences and 4 mentions for Polyrizon. Polyrizon's average media sentiment score of 1.87 beat Anixa Biosciences' score of 0.91 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Polyrizon	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Polyrizon's return on equity of 0.00% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Polyrizon	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	N/A	N/A	-$10.93M	-$0.31	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Anixa Biosciences presently has a consensus price target of $8.50, suggesting a potential upside of 198.25%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Anixa Biosciences is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

29.1% of Anixa Biosciences shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Anixa Biosciences has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, Polyrizon has a beta of -1.91, suggesting that its stock price is 291% less volatile than the broader market.

Summary

Anixa Biosciences beats Polyrizon on 7 of the 11 factors compared between the two stocks.

How does Polyrizon compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

In the previous week, Polyrizon had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 4 mentions for Polyrizon and 2 mentions for Telomir Pharmaceuticals. Polyrizon's average media sentiment score of 1.87 beat Telomir Pharmaceuticals' score of 1.31 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telomir Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Polyrizon	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Polyrizon's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
Polyrizon	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Telomir Pharmaceuticals has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market. Comparatively, Polyrizon has a beta of -1.91, meaning that its share price is 291% less volatile than the broader market.

Summary

Polyrizon beats Telomir Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Get Polyrizon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLRZ vs. The Competition

Export

Metric	Polyrizon	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.92M	$3.62B	$6.85B	$12.21B
Dividend Yield	N/A	2.21%	2.66%	6.23%
P/E Ratio	N/A	20.93	26.04	24.36
Price / Sales	N/A	349.16	551.95	103.70
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	0.98	8.71	10.98	6.49
Net Income	-$3.34M	$23.87M	$3.57B	$336.61M
7 Day Performance	-3.34%	4.23%	3.06%	0.90%
1 Month Performance	-25.74%	1.71%	0.72%	-0.36%
1 Year Performance	187.55%	69.92%	36.82%	31.26%

Polyrizon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLRZ Polyrizon	0.9993 of 5 stars	$12.75 +11.1%	N/A	+158.9%	$23.92M	N/A	N/A	N/A	News Coverage Positive News Analyst Downgrade
PLYX Polaryx Therapeutics	4.3581 of 5 stars	$2.32 flat	$10.00 +331.0%	N/A	$109.11M	N/A	N/A	11	Positive News Gap Up
FTLF FitLife Brands	4.8903 of 5 stars	$11.27 flat	$21.50 +90.8%	-13.5%	$105.83M	$81.46M	18.66	20	Positive News
AADI Aadi Bioscience	N/A	$4.22 +1.2%	N/A	+115.5%	$104.22M	$25.07M	N/A	40	High Trading Volume
ANIX Anixa Biosciences	4.317 of 5 stars	$2.91 flat	$8.50 +192.1%	-14.6%	$99.00M	$210K	N/A	5	Positive News Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLRZ) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Polyrizon (PLRZ) Competitors

PLRZ vs. PLYX, FTLF, AADI, ANIX, and TELO

How does Polyrizon compare to Polaryx Therapeutics?

Summary

How does Polyrizon compare to FitLife Brands?

Summary

How does Polyrizon compare to Aadi Bioscience?

Summary

How does Polyrizon compare to Anixa Biosciences?

Summary

How does Polyrizon compare to Telomir Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRZ vs. The Competition

Polyrizon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Polyrizon (PLRZ) Competitors

PLRZ vs. PLYX, FTLF, AADI, ANIX, and TELO

How does Polyrizon compare to Polaryx Therapeutics?

Does the media prefer PLRZ or PLYX?

Is PLRZ or PLYX more profitable?

Do analysts rate PLRZ or PLYX?

Which has preferable valuation and earnings, PLRZ or PLYX?

Summary

How does Polyrizon compare to FitLife Brands?

Which has more risk and volatility, FTLF or PLRZ?

Do institutionals & insiders believe in FTLF or PLRZ?

Does the media favor FTLF or PLRZ?

Is FTLF or PLRZ more profitable?

Which has better valuation & earnings, FTLF or PLRZ?

Do analysts recommend FTLF or PLRZ?

Summary

How does Polyrizon compare to Aadi Bioscience?

Does the media refer more to AADI or PLRZ?

Do institutionals and insiders hold more shares of AADI or PLRZ?

Do analysts prefer AADI or PLRZ?

Which has more risk & volatility, AADI or PLRZ?

Which has preferable valuation & earnings, AADI or PLRZ?

Is AADI or PLRZ more profitable?

Summary

How does Polyrizon compare to Anixa Biosciences?

Does the media refer more to ANIX or PLRZ?

Is ANIX or PLRZ more profitable?

Which has stronger earnings and valuation, ANIX or PLRZ?

Do analysts prefer ANIX or PLRZ?

Do institutionals & insiders hold more shares of ANIX or PLRZ?

Which has more volatility & risk, ANIX or PLRZ?

Summary

How does Polyrizon compare to Telomir Pharmaceuticals?

Which has stronger valuation & earnings, TELO or PLRZ?

Does the media refer more to TELO or PLRZ?

Is TELO or PLRZ more profitable?

Do analysts rate TELO or PLRZ?

Which has more volatility and risk, TELO or PLRZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRZ vs. The Competition

Polyrizon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools